Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide

Molecular Carcinogenesis

Volumn 26, Issue 2, 1999, Pages 100-118

  Jeffy, Brandon D ^a   Schultz, Elizabeth U ^a   Selmin, Ornella ^a   Gudas, Jean M ^b   Bowden, G Tim ^a,c,d   Romagnolo, Donato ^a,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aromatic hydrocarbon receptor; Benzo a pyrene; BRCA 1; Sporadic breast cancer

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 7,8 DIHYDROXYBENZO[A]PYRENE 9,10 OXIDE; ALPHA NAPHTHOFLAVONE; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; BRCA1 PROTEIN; CYTOCHROME P450; DIHYDROXYBENZO[A]PYRENE OXIDE; ESTROGEN RECEPTOR; MESSENGER RNA; POLYCYCLIC AROMATIC HYDROCARBON;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; WESTERN BLOTTING;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; BENZO(A)PYRENE; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, RIBOSOMAL; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0032836490     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199910)26:2<100::AID-MC5>3.0.CO;2-1     Document Type: Article

References (63)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-122.
3. Castilla LH, Couch FJ, Edros MR, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387-394.
4. Rao VN, Shao N, Ahmad M, Shyam C, Reddy P. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996;12:523-528.
5. Monteiro ANA, August A, Hanafusa H. Evidence for a trans-criptional activation function of BRCA-1 C-terminal region. Proc Natl Acad Sci USA USA 1996;93: 13595-13599.
6. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WF. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996;56:3168-3172.
7. Wilson CL, Thomsen J, Hoivik DJ, et al. Aryl hydrocarbon (Ah) nonresponsiveness in estrogen receptor-negative MDA-MB-231 cells is associated with expression of a variant ARNT protein. Arch Biochem Biophys 1997;346:65-73.
8. Coene E, Van Oostveldt P, Willems K, van Emmelo J, De Potter CR. BRCA-1 is localized in cytoplasmic tube-like invaginations in the nucleus. Nat Genet 1997;16:122-124.
9. Kinzler KW, Vogelstein B. Cancer-susceptibility genes: Gatekeepers and caretakers. Nature 1997;386:761.
10. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear localization and phosphorylation state are initiated by DNA damage. Cell 1997;90:1-20.
11. Sharan SK, Morimatsu M, Albrecht U, et al. Embyonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:804-810.
12. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012.
13. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Genetics. 1995;9:439-443.
14. Thompson ME, Jensen RA, Obermiller PS, Paige PS, Holt DL Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-450.
15. Xu CF, Solomon E. Mufations of the BRCA1 gene in human cancer. Semin Cancer Biol 1996;7:33-40.
16. Andres JL, Fan S, Turkel GJ, et al. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998;16;2229-2241.
17. Fan S, Twu N-F, Wang J-A, et al. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. Int J Cancer 1998;77: 600-609.
18. Ronai Z, Gradia S, el-Bayoumy K, Amin S, Hecht SS. Contrasting incidence of ras mutations in rat mammary and mouse skin tumors induced by anti-benzo[c]phenanthrene-3,4-diol-1,2-epoxide. Carcinogenesis 1994;15(10): 2113-2116.
19. Batsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104:569-577.
20. Krishnan V, Porter W, Santostefano M, Wang X, Safe S. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol Cell Biol 1995;15(12): 6710-6719.
21. Spink DC, Eugster HP, Lincoln DW, et al. 17-Beta-estradiol hydroxylation catalyzed by human cytochrome P4501A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 1992;293:342-348.
22. Hoivik D, Willett K, Wilson C, Safe S. Estrogen does not inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells. J Biol Chem 1997;272:30270-30274.
23. Wei Q, Gu J, Cheng L, et al. Benzo[a]pyrene diol epoxideinduced chromosomal aberrations and risk of lung cancer. Cancer Res 1996;56:3975-3979.
24. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-432.
25. Harper N, Wang X, Liu H, Safe S. Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol Cell Endocrinol 1994;104:47-55.
26. 2+-mediated endonuclease activation. Science 1988;242:256-259.
27. Hord NG, Perdew GH. Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: Characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator. Mol Pharmacol 1994;46:618-626.
28. Butler AP, Johnson DG, Kumar AP, Narayan S, Wilson SH, MacLeod MC. Disruption of transcription in vitro and gene expression in vivo by DNA adducts derived from a benzo[a]pyrene diol epoxide located in heterologous sequences. Carcinogenesis 1997;18:239-244.
29. Chakravarti D, Pelling JC, Cavalieri EL, Rogan EG. Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic sites. Proc Natl Acad Sci USA 1995;92:10422-10426.
30. Vaziri C, Faller DV. A benzo[a]pyrene-induced cell cycle checkpoint resulting in p53-independent G1 arrest in 3T3 fibroblasts. J Biol Chem 1997;272:2762-2769.
31. Gudas JM, Nguyen H, Li T, Cowen KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561-4565
32. Romagnolo D, Annab LA, Lyon TT, et al. Estrogen upregulation of expression of BRCA1 with no effect on localization. Mol Carcinog 1998;22:102-109.
33. Puissant C, Houdebine LM. An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Biotechniques 1990;8:148-149.
34. Stampfer MR, Bartley JC. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proc Natl Acad Sci USA 1985;82:2394-2398.
35. Bral CM, Ramos KS. Identification of benzo[a]pyrene-inducible cis-acting elements within c-Ha-ras transcriptional regulatory sequences. Mol Pharmacol 1997;52:974-982.
36. Xu C, Brown MA, Chambers JA, Griffiths B, Nicolai H, Solomon E. Distinct Transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet 1995;4: 2259-2264.
37. Kamps C, Safe S. Binding of polynuclear aromatic hydrocarbons to the rat 4S cytosolic binding protein: Structure-activity relationships. Cancer Lett 1987;4:129-137.
38. Zhao W, Ramos KS. Inhibition of DNA synthesis in primary cultures of adult rat hepatocytes by benzo[a]pyrene and related aromatic hydrocarbons: Role of Ah receptor-dependent events. Toxicology 1995;99:179-189.
39. Piskorska-Pliszczynska J, Keys B, Safe S, Newman MS. The cytosolic receptor binding affinity and AhR induction potencies of 29 polynuclear aromatic hydrocarbons. Toxicol Lett 1986;34:67-74.
40. Maher VM, Patton JD, Yang JL et al. Mutations and homologous recombination induced in mammalian cells by metabolites of benzo[a]pyrene and 1-nitropyrene. Environ Health Perspect 1987;76:33-39.
41. Leadon SA, Stampfer MR, Bartley J. Production of oxidative DNA damage during the metabolic activation of benzo[a]-pyrene in human mammary epithelial cells correlates with cell killing. Proc Natl Acad Sci USA 1988;85:4365-4368.
42. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol 1994;139:1001-1007.
43. Spink DC, Spink BC, Cao JQ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial and breast tumor cells. Carcinogenesis 1998;19:291-298.
44. Dohr O, Vogel C, Abel J. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MD-231 cells. Arch Biochem Biophys 1995;321:405-412.
45. Philpott NJ, Turner AJC, Scopes J et al. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 1996;87:2244-2251.
46. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: Release of cytochrome C from mithocondria blocked. Science 1997;275:1129-1132.
47. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/p53, and BRCA2/p53 nullizygous embryos. Genes Dev 1997;11:1226-1241.
48. Hakem R, de la Pompa JL. Elia A, Potter J, Mak TW. Partial rescue of BRCA1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 1997;16:298-302.
49. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994;72:537-545.
50. Gasiewicz TA, Rucci G. α-Naphthoflavone acts as an antagonist 2,3,7,8-tetrochlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Mol Pharmacol 1991;40:607-612.
51. Horton AW. Epidemiologic evidence for the role of indoor tobacco smoke as an initiator of human breast carcinogenesis. Cancer Detect Prev 1992;16:119-127.
52. Lemon HM. Breast cancer and cigarette smoking: A hypothesis. Am J Epidemiol 1992;135:1184-1185.
53. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996;93:3294-3296.
54. Safe S, Krishnan V. Chlorinated hydrocarbons: Estrogens and antiestrogens. Toxicol Lett 1995;731-736.
55. Thomsen JS, Wang X, Hines RN, Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis 1994;15:933-937.
56. Spink DC, Spink BC, Cao JQ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998;19: 291-298.
57. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997;11:1569-1580.
58. Kobayashi A, Sogawa K, Fujii-Kuriyama Y. Cooperative interaction between AhR-Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene. J Biol Chem 1996;271:12310-12316.
59. Xu C, Chambers JA, Solomon E. Complex regulation of the BRCA1 gene. J Biol Chem 1997;272:20994-20997.
60. Fukunaga BN, Probst MR, Reisz-Porszasz S, Hankinson O. Identification of functional domains of the aryl hydrocarbon receptor. J Biol Chem 1995;270:29270-29278.
61. Nebert DW, Petersen DD, Fornace JrAJ. Cellular responses to oxidative stress: The Ah gene battery as a paradigm. Environ Health Perspect 1990;88:13-25.
62. Wang X, Porter W, Krishnan V, Narasimhan, TR, Safe S. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol Cell Endocrinol 1993; 96:159-166.
63. MacLeod MC, Powell KL, Tran N. Binding of the transcription factor Sp1 to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis 1995;16: 975-983.